Nature: The gender differences in COVID-19 have an immunological basis

There is growing evidence of gender differences in clinical performance and transition in PATIENT COVID-19 patients.
, are there differences in the immune response to the virus between different genders? Is this difference the cause of the relative susceptibleness of COVID-19 men? Recently, the journal Nature published a study online by Akico Iwasaki of Yale University School of Medicine and his team entitled "Sex differences inimmune responses that underlie COVID-19 disease outcomes".
the report explores the gender differences in COVID-19 and the possible immunological mechanisms behind them.
DOI: 10.1038/s41586-020-2700-3 Researchers tested viral load, SARS-CoV-2 specific antibody titularity, plasma cell factors, and blood cell esotypes in patients with COVID-19.
results showed higher levels of several important inflammatory congenital immunodeficiration factors and cytokines in male patients, which may be associated with a higher number of non-classical monocytes.
the first sample of the virus load, anti-SARS-CoV-2 antibody titration, the researchers found that female patients have a stronger T-cell response.
of cd8-T cells increased significantly in female patients, while in male patients they were comparable to healthy populations.
analyzing patients' clinical performance and transition, the researchers found that poor T-cell response in male patients was associated with disease development, while high innocular immunocytokine levels in female patients were associated with a worsening of COVID-19.
, there was a significant age-negative correlation in T-cell response in male patients.
differences in disease progression in patients with the disease these data show key differences in immune responses between men and women in the early stages of SARS-COV-2 infection, and reveal possible immunological mechanisms.
Although this study has some limitations, it can provide ideas for further study of COVID-19 gender differences, and provide the basis for more efficient COVID-19 prevention, nursing, treatment and prognosios research.
overall, male patients may be more likely to need treatment for SARS-CoV-2's T-cell immune response, while female patients may be better suited to treatments that inhibit innate immune activation early in the disease.
resources: sic. s.1. Sex differences in immune responses that underlie COVID-19 disease outcomes.